almeda pharma

Almeda Pharmaceuticals AG Receives Marketing Authorisation in Moldova for Three Dipharma Orphan Medicines for Rare Metabolic Disorders

Contact Us for Details

Your inquiries are important to us, and our dedicated team is here to provide you with professional assistance.

Miglustat, Nitisinone and Sapropterin Dipharma approved for Gaucher disease type 1, Niemann–Pick disease type C, hereditary tyrosinaemia type 1 and phenylketonuria; launch preparations under way

Zug, Switzerland, 16 October 2026 – Almeda Pharmaceuticals AG today announced that the Medicines and Medical Devices Agency of the Republic of Moldova (AMDM) has granted marketing authorisation for three orphan medicines from Dipharma: Miglustat Dipharma, Nitisinone Dipharma and Sapropterin Dipharma. The medicines treat rare inherited metabolic disorders that require continuous, often lifelong, therapy. Almeda Pharmaceuticals AG is the marketing authorisation holder for all three medicines in Moldova.

AMDM granted the authorisations under Order No. Rg04-227 of 29 July 2026 and Order No. Rg04-261 of 1 September 2026. Each authorisation is valid for five years.

“Getting these medicines authorised in Moldova is an important step in our mission to make rare disease treatments available to the patients who need them,” said Ala Tocarciuc, Chief Executive Officer of Almeda Pharmaceuticals AG. “People living with these conditions depend on uninterrupted treatment. Our goal is that every patient in Moldova can access modern therapy without delay.”

New treatment options for patients with rare diseases

All three medicines belong to the therapeutic group of alimentary tract and metabolism products (ATC A16AX):

•     Miglustat is indicated for type 1 Gaucher disease and Niemann–Pick disease type C – inherited disorders in which fatty substances build up in cells and damage organs such as the liver, spleen, bones and brain.

•     Nitisinone is indicated for hereditary tyrosinaemia type 1, a disorder in which the body cannot break down the amino acid tyrosine, leading to serious liver and kidney damage if untreated.

•     Sapropterin is indicated for hyperphenylalaninaemia in patients with phenylketonuria (PKU) and tetrahydrobiopterin (BH4) deficiency, conditions in which high phenylalanine levels can harm brain development.

Because these diseases need continuous treatment, patients depend on a reliable supply of high-quality medicines. The new authorisations expand the treatment options available to patients and physicians in Moldova.

Availability

Almeda Pharmaceuticals AG is now preparing supply, and the medicines are expected to be available in Moldova soon. The company will work closely with the medical community and healthcare institutions to ensure patients receive their treatment on time and without interruption.

About Almeda Pharmaceuticals AG

Founded in 2013 and headquartered in Zug, Switzerland, Almeda Pharmaceuticals AG partners with pharmaceutical manufacturers to bring specialty medicines, rare disease treatments and food supplements to patients in the CIS region. Its portfolio covers oncology, transplantology, central nervous system disorders, antimicrobials and rare diseases. For more information, visit www.almedapharma.ch.

About Dipharma

Dipharma SA is a Swiss specialty pharmaceutical company based in Chiasso that develops high-quality, improved medicines for rare inherited metabolic diseases, including phenylketonuria, Gaucher disease, hereditary tyrosinaemia type 1 and urea cycle disorders. Part of a family-owned group of companies, Dipharma aims to make these treatments accessible to patients worldwide at a reasonable cost. For more information, visit www.dipharma.ch.

Media contact

Almeda Pharmaceuticals AG

Email: office@almedapharma.ch

Web: www.almedapharma.ch